OligoDOMTM: a T-cell response-enhancing platform applied to cancer immunotherapy
BackgroundNeoepitopes derived (0) from tumors are attractive cancer immunotherapy targets, especially when combined with immune checkpoint inhibitors (CPIs). Vaccines using lipid nanoparticle (LNP)-encapsulated mRNA to deliver neoepitopes have shown en…